c-Myc

VPC-70063 (Thiourea, N-[3,5-bis(trifluoromethyl)phenyl]-N'-(phenylmethyl)-) is an inhibitor of c-Myc-MAX. VPC-70063 exhibits Myc-Max transcriptional activity inhibition of 106% with an IC50 of 8.9 μM and Myc-Max/UBE2C downstream pathway inhibition of 94%. VPC-70063 can be used for studies about anticancer.

10074-A4 is a c-Myc binding compound that associates with c-Myc370–409 and behaves like a “ligand cloud” around a “protein cloud”, with distinct features from that of a non-binding ligand.

MYCi361 (NUCC-0196361) is an inhibitor of MYC (binding to MYC with Kd of 3.2 μM).

10058-F4 (c-Myc Inhibitor) is a cell-permeable thiazolidinone that specifically inhibits the c-Myc-Max interaction and prevents transactivation of c-Myc target gene expression; induces cell-cycle arrest and apoptosis.

WBC100 (14-D-Valine-TPL) is a potent, selective, and orally active c-Myc glue degrader that targets the ubiquitin E3 ligase CHIP-mediated 26S proteasome pathway, primarily utilized in research for c-Myc overexpressing tumors [1].

Moracin C and moracin D, new phytoalexins from diseased mulberry, are antifungal compounds. Moracin may be protective influence in tumor promotion, utilization of Moracin may open a new avenue in the treatment of tumerigenesis.

MYC-RIBOTAC, a ribonuclease-targeting chimera (RIBOTAC) specific to the MYC internal ribosome entry site (IRES), comprises an MYC mRNA-binding element tethered to a small molecule that recruits and activates RNase L1. This interaction promotes the degradation of MYC mRNA, subsequently reducing MYC protein levels and inducing apoptosis, thereby presenting potential applications in anticancer research [1].

NY2267 (Acetic acid, 2-[[6-[2-(cyclohexylamino)-1-[[(4-methoxyphenyl)methyl](2-pyridinylcarbonyl)amino]-2-oxoethyl]-2-naphthalenyl]oxy]-, 1,1-dimethylethyl ester) is a disruptor of Myc-Max interaction, with an IC50 of 36.5 μM.

m-Se3 is a potent, selective inhibitor of c-MYC transcription with demonstrated capability to inhibit tumor growth and exhibit anti-cancer activity [1].

Aaptamine functions as a proteasome inhibitor, it activates p21 promoter in a p53-independent manner.

Moracin treatment can inhibit the double 12-O-tetradecanoylphorbol 13-acetate (TPA) treatment-induced morphological changes reflecting inflammatory response, including leucocyte infiltration, hyperplasia and cell proliferation; moracin treatment furthermo

Trachelogenin ((-)-Trachelogenin), isolated from Combretum fruticosum, is an HCV entry inhibitor with anti-proliferative effects. Its mechanism is related to affecting the phosphorylation of key proteins such as β-Catenin, c-Myc and GSK3 in the β-Catenin signaling pathway. chemical and concentration-dependent. Trachelogenin has antiviral, anti-inflammatory and analgesic activities with IC50 of 0.325 and 0.259 μg/mL in HCVcc and HCVpp models, respectively.

Coronarin D shows promising antifungal activity against C. albicans in vitro, the minimum inhibitory concentration (MIC) and the minimum fungicidal concentration (MFC) were 2 and 4 mg/mL, respectively; it is active against tested Gram-positive bacteria, i

MDEG-541 is a potent MYC-MAX degrader that exhibits antiproliferative activity by downregulating the expression of GSPT1, MYC, GSPT2, and PLK1 proteins [1].

CBP/EP300-IN-2 is an inhibitor of CBP/EP300 (IC50s: 1.07 nM and 5.96 nM for CBP/HTRF and Myc).

MYCi975 (NUCC-0200975) is an orally active inhibitor of MYC.

EN4 (EN4 MYC inhibitor) MYC inhibitor is a covalent ligand that targets cysteine 171 (C171) of MYC. It is selective for c-MYC over N-MYC and L-MYC, and inhibits MYC transcriptional activity, downregulates MYC targets, and impairs tumorigenesis.

MYCMI-6 (NSC-354961) is a potent and selective inhibitor of endogenous MYC:MAX protein interactions，reduces proliferation and induces massive apoptosis in tumor tissue from a MYC-driven xenograft tumor model without severe side effects.

sAJM589 is a Myc inhibitor(IC50: 1.8 μM).

KSI-3716 is an inhibitor of c-Myc.

APTO-253 (LOR-253) inhibits c-Myc expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and apoptosis in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through the induction of the KLF4 tumor suppressor.

CPI0610 (CPI-0610) is an effective, specific, and cell-active BET bromodomain inhibitor CPI-0610 inhibits BRD4-BD1 (IC50: nM).

10074-G5 is an inhibitor of c-Myc-Max dimerization.

IRES-C11 is a specific inhibitor of translation that targets the internal ribosome entry site (IRES) of the c-MYC gene. It functions by blocking the interaction between heterogeneous nuclear ribonucleoprotein A1, a trans-acting factor required for c-MYC IRES activity, and its corresponding IRES. Notably, IRES-C11 does not inhibit the IRES activity of BAG-1, XIAP, and p53.

BTYNB (MDK6620) is an inhibitor of the oncofetal mRNA-binding protein IMP1 (IC50 = 5 μM for IMP1 binding to c-Myc mRNA). MDK6620 downregulates β-TrCP1 mRNA and reduces activation of nuclear transcriptional factors-kappa B (NF-κB). It disrupts this enhancer function by impairing IGF2 mRNA-binding protein 1 (IGF2BP1)-RNA association

c-Myc inhibitor 11 (Compound 67e), a c-MYC inhibitor (p EC 50 : 6.4), exhibits high clearance, a moderate volume of distribution, and a short half-life in rat pharmacokinetic assays, making it suitable for cancer research [1].

Compound 67h, also known as c-Myc inhibitor 12, is a potent inhibitor of c-Myc, exhibiting a pEC50 value of 6.4 [1].

Lusianthridin is a natural product from Dendrobium venustum. Lusianthridin exhibits anti-migratory property at nontoxic concentrations. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling.

ML327 is a MYC blocker. ML327 can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).

Mycro 3 is potent and selective for c-Myc in whole cell assays.

KJ Pyr 9 is an MYC inhibitor (Kd: 6.5 nM in vitro assay).

Nicotinamide N-oxide (Nicotinamide 1-oxide) is recognized as an in vivo metabolite of nicotinamide which is a precurser of nicotinamide-adenine dinucleotide (NAD+) in animals. The enzyme that catalyzes the reduction of nicotinamide N-oxide to nicotinamide in the liver is xanthine oxidase.